Related Experiment Videos
Apoptotic pathways of epothilone BMS 310705
Denise Uyar1, Nagio Takigawa, Tarek Mekhail
1The Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center/R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA. uyard@ccf.org
Gynecologic Oncology
|October 8, 2003
Summary
BMS 310705, a novel epothilone B analog, effectively induces apoptosis and reduces cancer cell survival. It activates the mitochondrial pathway, showing promise in preclinical models resistant to standard therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- BMS 310705 is a novel, water-soluble epothilone B analog.
- Currently undergoing Phase I clinical trials for various malignancies.
- Investigated in a cell culture model resistant to platinum/paclitaxel therapy.
Purpose of the Study:
- To evaluate the apoptosis pathway induced by BMS 310705.
- To assess the efficacy of BMS 310705 in a platinum/paclitaxel-refractory cancer model.
Main Methods:
- Cell culture treated with BMS 310705.
- Apoptosis, cell survival, and caspase activity assays (caspase-3, -8, -9).
- Mitochondrial cytochrome c release analysis.
Main Results:
- BMS 310705 induced apoptosis in >25% of cells within 24 hours.
- Significantly reduced cell survival compared to paclitaxel (P < 0.02).
- Increased caspase-9 and -3 activity, with cytochrome c release at 12 hours, indicating mitochondrial pathway activation.
Conclusions:
- BMS 310705 effectively induces apoptosis and decreases survival in the tested model.
- The drug utilizes the mitochondrial-mediated pathway for apoptosis.
- Demonstrates potential against malignancies refractory to conventional chemotherapy.